Telomir Pharmaceuticals (NASDAQ:TELO - Get Free Report) is anticipated to announce its earnings results before the market opens on Monday, May 12th. Analysts expect the company to announce earnings of ($0.10) per share for the quarter.
Telomir Pharmaceuticals (NASDAQ:TELO - Get Free Report) last posted its quarterly earnings data on Tuesday, February 4th. The company reported ($0.10) earnings per share for the quarter, missing analysts' consensus estimates of ($0.05) by ($0.05). On average, analysts expect Telomir Pharmaceuticals to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Telomir Pharmaceuticals Trading Down 1.2 %
Telomir Pharmaceuticals stock traded down $0.03 during midday trading on Friday, hitting $2.49. The stock had a trading volume of 105,442 shares, compared to its average volume of 132,841. Telomir Pharmaceuticals has a 52-week low of $2.35 and a 52-week high of $8.40. The company has a market capitalization of $74.11 million, a PE ratio of -4.29 and a beta of 0.17. The firm's fifty day moving average is $3.26 and its two-hundred day moving average is $4.08.
Hedge Funds Weigh In On Telomir Pharmaceuticals
An institutional investor recently raised its position in Telomir Pharmaceuticals stock. Bank of America Corp DE lifted its position in Telomir Pharmaceuticals, Inc. (NASDAQ:TELO - Free Report) by 283.9% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 14,713 shares of the company's stock after purchasing an additional 10,880 shares during the quarter. Bank of America Corp DE's holdings in Telomir Pharmaceuticals were worth $61,000 at the end of the most recent reporting period.
Wall Street Analysts Forecast Growth
Several brokerages have recently commented on TELO. RODMAN&RENSHAW upgraded shares of Telomir Pharmaceuticals to a "strong-buy" rating in a research report on Thursday, February 20th. Rodman & Renshaw assumed coverage on Telomir Pharmaceuticals in a research note on Friday, February 21st. They issued a "buy" rating and a $15.00 price objective for the company.
View Our Latest Report on TELO
About Telomir Pharmaceuticals
(
Get Free Report)
Telomir Pharmaceuticals, Inc, a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems.
Read More
Before you consider Telomir Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Telomir Pharmaceuticals wasn't on the list.
While Telomir Pharmaceuticals currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.